Cancer & Metabolism publishes selected collections of research articles, conference proceedings, reviews and reports as supplements. While we build our new sites all supplements will be available here.
Chi Van Dang, Editor Emeritus
Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.
"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."
Dr. Michael Pollak, co-Editor-in-Chief
Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.
"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."
Dr. Matthew G. Vander Heiden, co-Editor-in-Chief
Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. His other roles include Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C), complementing his past awards in molecular oncology.
Michael Pollak, McGill University, Canada
Matthew Vander Heiden, Massachusetts Institute of Technology, USA
Kevin Brindle, University of Cambridge, UK
Navdeep Chandel, Northwestern University, USA
Ralph DeBerardinis, University of Texas Southwestern Medical Center, USA
Eyal Gottlieb, Beatson Institute for Cancer Research, UK
Chi Van Dang, University of Pennsylvania, USA
Aims and scope
Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer including Molecular biology and genetics of cancer.
Efficient peer review
We recognize that scientifically sound, high-quality manuscripts often receive negative decisions from high-impact journals on the basis of perceived general interest levels or the absence of extensive mechanisms supporting research hypotheses. As a niche journal, Cancer & Metabolism will consider rapid publication of such manuscripts if they are submitted together with the original peer reviewer reports, letter of rejection, and a brief rebuttal.
This review highlights the recent advances on the mathematical models of cancer metabolism.
Cross journal article collection
Guest edited by Navdeep Chandel (on behalf of Cancer & Metabolism), Martin Brand, Andrew Murray, Jodi Nunnari and Peter Walter, this cross journal collection focuses on all aspects of mitochondrial function in cancer and metabolism.
Annual Journal Metrics
63 days to first decision for reviewed manuscripts only
55 days to first decision for all manuscripts
123 days from submission to acceptance
27 days from acceptance to publication
145 Altmetric Mentions